Precision Radionuclide Therapy

KENNEWICK, Wash., July 6, 2026 Vivos Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the...

KENNEWICK, Wash., June 5, 2026 Vivos Inc. announced the submission of an Early Feasibility Investigational Device Exemption (IDE) application...